

# Heather H Cheng

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3048978/heather-h-cheng-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78  
papers

6,604  
citations

25  
h-index

81  
g-index

85  
ext. papers

8,492  
ext. citations

6.9  
avg, IF

5.57  
L-index

#	Paper	IF	Citations
78	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , <b>2015</b> , 161, 1215-1228	56.2	1765
77	MicroRNA profiling: approaches and considerations. <i>Nature Reviews Genetics</i> , <b>2012</b> , 13, 358-69	30.1	1185
76	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 443-53	59.2	791
75	Quantitative and stoichiometric analysis of the microRNA content of exosomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 14888-93	11.5	676
74	Plasma processing conditions substantially influence circulating microRNA biomarker levels. <i>PLoS ONE</i> , <b>2013</b> , 8, e64795	3.7	217
73	Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 69, 992-5	10.2	175
72	lazarus is a novel pbx gene that globally mediates hox gene function in zebrafish. <i>Molecular Cell</i> , <b>2000</b> , 6, 255-67	17.6	126
71	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. <i>PLoS ONE</i> , <b>2013</b> , 8, e69239	3.7	124
70	Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 4492-4505	15.9	102
69	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2798-2811	2.2	80
68	Envelope Determinants for Dual-Receptor Specificity in Feline Leukemia Virus Subgroup A and T Variants. <i>Journal of Virology</i> , <b>2006</b> , 80, 12431-12431	6.6	78
67	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 19, 134-143	7.3	71
66	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. <i>European Urology</i> , <b>2018</b> , 73, 687-693	10.2	70
65	Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. <i>European Urology</i> , <b>2019</b> , 76, 452-458	10.2	69
64	Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2015</b> , 18, 122-7	6.2	63
63	A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. <i>PLoS ONE</i> , <b>2018</b> , 13, e0198389	3.7	51
62	Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. <i>Oncotarget</i> , <b>2016</b> , 7, 82504-82510	3.3	47

61	Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2407-2417	2.2	44
60	Germline and Somatic Mutations in Prostate Cancer for the Clinician. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 515-521	7.3	42
59	SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1601-8	2.2	38
58	Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. <i>JAMA Oncology</i> , <b>2021</b> , 7, 107-110	13.4	34
57	Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. <i>PLoS ONE</i> , <b>2020</b> , 15, e0233260	3.7	29
56	Glucocorticoids and prostate cancer treatment: friend or foe?. <i>Asian Journal of Andrology</i> , <b>2014</b> , 16, 354-8	8.8	29
55	Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2017</b> , 26, 222-227	4	26
54	Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. <i>Advances in Urology</i> , <b>2013</b> , 2013, 317190	1.6	23
53	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 275-282.e1	3.3	22
52	Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	21
51	Prostate Cancer Screening in a New Era of Genetics. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 625-628	3.3	19
50	Ethnic disparities among men with prostate cancer undergoing germline testing. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 80.e1-80.e7	2.8	19
49	Role of maximal endoscopic resection before cystectomy for invasive urothelial bladder cancer. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 287-91	3.3	16
48	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, 811-819	2.3	16
47	Advanced clinical states in prostate cancer. <i>Urologic Clinics of North America</i> , <b>2012</b> , 39, 561-71	2.9	15
46	Genetic and biochemical analyses of receptor and cofactor determinants for T-cell-tropic feline leukemia virus infection. <i>Journal of Virology</i> , <b>2002</b> , 76, 8069-78	6.6	15
45	Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. <i>Prostate</i> , <b>2018</b> , 78, 121-127	4.2	15
44	Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2018</b> , 38, 372-381	7.1	15

43	Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. <i>JCI Insight</i> , <b>2019</b> , 5,	9.9	14
42	A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling. <i>Prostate</i> , <b>2016</b> , 76, 1303-11	4.2	14
41	Genetic Testing in Prostate Cancer. <i>Current Oncology Reports</i> , <b>2020</b> , 22, 5	6.3	10
40	Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>JCO Precision Oncology</i> , <b>2018</b> , 2018,	3.6	10
39	Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. <i>Prostate</i> , <b>2019</b> , 79, 701-708	4.2	9
38	Envelope determinants for dual-receptor specificity in feline leukemia virus subgroup A and T variants. <i>Journal of Virology</i> , <b>2006</b> , 80, 1619-28	6.6	9
37	Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3740-3742	2.2	9
36	Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. <i>Medical Oncology</i> , <b>2016</b> , 33, 77	3.7	8
35	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 83-93	2.8	8
34	Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes. <i>Bladder Cancer</i> , <b>2020</b> , 6, 71-81	1	8
33	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. <i>Prostate</i> , <b>2021</b> , 81, 433-439	4.2	8
32	Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2439-2440	12.9	8
31	Polyclonal Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer. <i>JCO Precision Oncology</i> , <b>2018</b> , 2,	3.6	8
30	CD8 T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. <i>Molecular Therapy</i> , <b>2020</b> , 28, 1238-1250	11.7	7
29	Feline leukemia virus T entry is dependent on both expression levels and specific interactions between cofactor and receptor. <i>Virology</i> , <b>2007</b> , 359, 170-8	3.6	7
28	Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.. <i>Lancet Oncology, The</i> , <b>2022</b> ,	21.7	7
27	The resounding effect of DNA repair deficiency in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 385-388	2.8	6
26	Nonresponse to neoadjuvant chemotherapy for muscle-invasive urothelial cell carcinoma of the bladder. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 210-3	3.3	6

25	Long-term survival in bone-predominant metastatic urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, e241-4	3.3	4
24	Inherited TP53 Variants and Risk of Prostate Cancer. <i>European Urology</i> , <b>2021</b> ,	10.2	4
23	Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. <i>PLoS ONE</i> , <b>2020</b> , 15, e0239686	3.7	4
22	Bladder Cancer Multidisciplinary Clinic (BCMC) Model Influences Disease Assessment and Impacts Treatment Recommendations. <i>Bladder Cancer</i> , <b>2019</b> , 5, 289-298	1	4
21	Complexities of Next-Generation Sequencing in Solid Tumors: Case Studies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 1150-1155	7.3	3
20	Hepatitis C infection and chemotherapy toxicity. <i>Journal of Oncology Pharmacy Practice</i> , <b>2019</b> , 25, 474-480		3
19	Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 486-493	6.2	2
18	Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , <b>2017</b> , 77, 1478-1488	4.2	2
17	Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy. <i>Journal of Hematology and Oncology</i> , <b>2015</b> , 8, 51	22.4	2
16	Barriers and facilitators of germline genetic evaluation for prostate cancer. <i>Prostate</i> , <b>2021</b> , 81, 754-764	4.2	2
15	Differential Activity of PARP Inhibitors in - Versus -Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	2
14	Germline contributions to metastatic prostate cancer. <i>Canadian Journal of Urology</i> , <b>2019</b> , 26, 19-21	0.8	2
13	Germline Testing in Prostate Cancer: When and Who to Test. <i>Oncology</i> , <b>2021</b> , 35, 645-653	1.8	1
12	Implementation of systematic germline genetic testing (GT) for metastatic prostate cancer (mPC) patients at the Puget Sound VA prostate oncology clinic.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1578-1578	7.2	1
11	Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, 144-154	3.3	1
10	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. <i>Prostate</i> , <b>2021</b> , 81, 1382-1389	4.2	1
9	Germline genetics of prostate cancer. <i>Prostate</i> , <b>2022</b> , 82,	4.2	1
8	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , <b>2021</b> , 79, 736-746	10.2	0

7	Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 6001-6011	12.9	○
6	Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 496.e1-496.e8	2.8	○
5	Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. <i>Prostate</i> , <b>2018</b> , 78, 1077	4.2	
4	Operationalizing Genetic Testing in the Care of Patients with Prostate Cancer <b>2022</b> , 61-73		
3	Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 352.e19-352.e24	2.8	
2	Genetic Contribution to Metastatic Prostate Cancer. <i>Urologic Clinics of North America</i> , <b>2021</b> , 48, 349-363	2.9	
1	A Patient-Centered Approach to Research Prioritization in Prostate Cancer.. <i>Journal of Urology</i> , <b>2022</b> , 101097JU00000000000002694	2.5	